Prognosis for adolescents with Hodgkin’s disease1
From 1972 to 1983, 68 adolescents, aged 12 to 20 years (median 17.6 years), with Hodgkin’s disease received treatment at the Cleveland Clinic. Although the overall male:female ratio was 1.2:1.0, male predominance was greater in younger adolescents. The histopathologic distribution was overwhelmingly nodular sclerosing (69%), but 24% were mixed cellularity, and 7% were lymphocyte-predominant. There was no statistical relationship between histopathology and survival. All patients were pathologically staged (PS): PS-I = 11 patients, PS-II = 26 patients, PS-III = 17 patients, and PS-IV = 14 patients. The overall five-year survival rate was 83%, and there was no significant difference between pathological stage and chance of survival. Treatment programs had been based on pathological staging, usually irradiation therapy for stages I and II, combination chemotherapy for stage IV, and both modalities combined for stage III. This therapy has resulted in an excellent five-year survival rate for these adolescents.